Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 14/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30142696 | 0.89 | MEN1 (0.40) | HDAC3HDAC1HPGDSMN1; SMN2 | |
| SCHEMBL29057138 | 0.89 | MEN1 (0.40) | HDAC3HDAC1HPGDSMN1; SMN2 | |
| SCHEMBL25143602 | 0.88 | NPC1 (0.47) | CYP3A4HDAC3HDAC1SMN1; SMN2HDAC2 | |
| SCHEMBL24072476 | 0.85 | MAPT (0.43) | CYP3A4HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL25063052 | 0.84 | HDAC3 (0.45) | CYP3A4HDAC3HDAC1HPGDSMN1; SMN2 | |
| SCHEMBL25063110 | 0.84 | HDAC3 (0.45) | CYP3A4HDAC3HDAC1HPGDSMN1; SMN2 | |
| SCHEMBL25063094 | 0.84 | HDAC3 (0.45) | CYP3A4HDAC3HDAC1HPGDSMN1; SMN2 | |
| SCHEMBL25063360 | 0.84 | HDAC3 (0.45) | CYP3A4HDAC3HDAC1HPGDSMN1; SMN2 | |
| SCHEMBL25063179 | 0.84 | HDAC3 (0.45) | CYP3A4HDAC3HDAC1HPGDSMN1; SMN2 | |
| SCHEMBL25063128 | 0.84 | HDAC3 (0.45) | CYP3A4HDAC3HDAC1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | CYP3A4 2625/4885HDAC3 1547/4885HDAC1 924/4885 |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | CYP3A4 2625/4885HDAC3 1547/4885HDAC1 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.